DE60128902D1 - Formulierungen zur verwendung in inhalationsvorrichtungen - Google Patents

Formulierungen zur verwendung in inhalationsvorrichtungen

Info

Publication number
DE60128902D1
DE60128902D1 DE60128902T DE60128902T DE60128902D1 DE 60128902 D1 DE60128902 D1 DE 60128902D1 DE 60128902 T DE60128902 T DE 60128902T DE 60128902 T DE60128902 T DE 60128902T DE 60128902 D1 DE60128902 D1 DE 60128902D1
Authority
DE
Germany
Prior art keywords
formulations
diameter
inhalation devices
formulation
particles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60128902T
Other languages
English (en)
Other versions
DE60128902T2 (de
Inventor
John Nicholas Staniforth
David Alexander Vodden Morton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vectura Ltd
Original Assignee
Vectura Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26071083&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60128902(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB0009468.0A external-priority patent/GB0009468D0/en
Application filed by Vectura Ltd filed Critical Vectura Ltd
Application granted granted Critical
Publication of DE60128902D1 publication Critical patent/DE60128902D1/de
Publication of DE60128902T2 publication Critical patent/DE60128902T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60128902T 2000-04-17 2001-04-17 Formulierungen zur verwendung in inhalationsvorrichtungen Expired - Lifetime DE60128902T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB0009468.0A GB0009468D0 (en) 2000-04-17 2000-04-17 Improvements in or relating to formulations for use in inhaler devices
GB0009468 2000-04-17
EP00113608 2000-06-27
EP00113608 2000-06-27
PCT/GB2001/001757 WO2001078696A2 (en) 2000-04-17 2001-04-17 Formulations for use in inhaler devices

Publications (2)

Publication Number Publication Date
DE60128902D1 true DE60128902D1 (de) 2007-07-26
DE60128902T2 DE60128902T2 (de) 2008-02-14

Family

ID=26071083

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60128902T Expired - Lifetime DE60128902T2 (de) 2000-04-17 2001-04-17 Formulierungen zur verwendung in inhalationsvorrichtungen

Country Status (9)

Country Link
EP (1) EP1276474B1 (de)
JP (1) JP2004500424A (de)
AT (1) ATE364381T1 (de)
AU (1) AU782841B2 (de)
CA (1) CA2406206C (de)
DE (1) DE60128902T2 (de)
ES (1) ES2288167T3 (de)
NZ (1) NZ521972A (de)
WO (1) WO2001078696A2 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7094545B2 (en) 2003-04-30 2006-08-22 Ferring Bv Pharmaceutical composition as solid dosage form and method for manufacturing thereof
SI1500390T1 (sl) 2003-07-25 2006-02-28 Ferring Bv Farmacevtski dezmopresinski sestavek kot trdna dozirna oblika in postopek za njegovo pripravo
US7018653B2 (en) 2003-12-29 2006-03-28 Ferring B.V. Method for preparing solid dosage form of desmopressin
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
GB0714134D0 (en) * 2007-07-19 2007-08-29 Norton Healthcare Ltd Dry-powder medicament
JP2010534248A (ja) 2007-07-21 2010-11-04 アルバニー モレキュラー リサーチ， インコーポレイテッド ５−ピリジノン置換インダゾール
CN103351390A (zh) 2007-11-21 2013-10-16 解码遗传Ehf公司 用于治疗肺部和心血管病症的联芳基pde4 抑制剂
EP2476680B1 (de) 2008-01-11 2014-08-27 Albany Molecular Research, Inc. (1-Azinon)-substituierte Pyrido-Indole
WO2010059836A1 (en) 2008-11-20 2010-05-27 Decode Genetics Ehf Substituted aza-bridged bicyclics for cardiovascular and cns disease
TWI491416B (zh) 2008-12-24 2015-07-11 Daiichi Sankyo Co Ltd 吸入用乾燥粉末醫藥組成物
US8673931B2 (en) 2009-01-26 2014-03-18 Abraham Fisher Bicyclic heterocyclic spiro compounds
PL2413902T3 (pl) * 2009-03-18 2020-01-31 Incarda Therapeutics, Inc. Dawki jednostkowe, aerozole, zestawy oraz sposoby leczenia chorób serca przez podawanie dopłucne
EP2969482B1 (de) 2013-03-15 2018-05-09 3D Systems, Inc. Dreidimensionales druckmaterialsystem
GB201305825D0 (en) 2013-03-28 2013-05-15 Vectura Ltd New use
US10806770B2 (en) 2014-10-31 2020-10-20 Monash University Powder formulation
EP3411030A4 (de) 2016-02-01 2019-09-04 InCarda Therapeutics, Inc. Elektronische überwachung mit inhalierter pharmakologischer therapie für das management von herzarrhythmien mit vorhofflimmern
ES3038913T3 (en) 2018-03-20 2025-10-15 Icahn School Med Mount Sinai Beta-carboline derivatives as dyrk1a inhibitors for the treatment of e.g. diabetes
ES3040411T3 (en) 2018-03-22 2025-10-30 Incarda Therapeutics Inc A novel method to slow ventricular rate
US10966943B2 (en) 2018-09-06 2021-04-06 Innopharmascreen Inc. Methods and compositions for treatment of asthma or parkinson's disease
EP3906233B1 (de) 2018-12-31 2024-01-31 Icahn School of Medicine at Mount Sinai Kinaseinhibitorverbindungen und zusammensetzungen und verfahren zur verwendung
US11007185B2 (en) 2019-08-01 2021-05-18 Incarda Therapeutics, Inc. Antiarrhythmic formulation
GB2641869A (en) 2023-08-30 2025-12-17 Envirohale Malta Holdings Ltd Nasal and pulmonary drug delivery

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4349542A (en) * 1979-06-08 1982-09-14 National Research Development Corporation Mixture containing active ingredient and dendritic crystalline sugar for tableting
DE4140689B4 (de) * 1991-12-10 2007-11-22 Boehringer Ingelheim Kg Inhalationspulver und Verfahren zu ihrer Herstellung
GB9322014D0 (en) * 1993-10-26 1993-12-15 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
DE4425255A1 (de) * 1994-07-16 1996-01-18 Asta Medica Ag Formulierung zur inhalativen Applikation
GB9501841D0 (en) * 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
ES2192866T3 (es) * 1998-11-13 2003-10-16 Jago Res Ag Polvo seco para inhalacion.

Also Published As

Publication number Publication date
ATE364381T1 (de) 2007-07-15
EP1276474A2 (de) 2003-01-22
AU782841B2 (en) 2005-09-01
DE60128902T2 (de) 2008-02-14
AU4860101A (en) 2001-10-30
JP2004500424A (ja) 2004-01-08
NZ521972A (en) 2004-06-25
EP1276474B1 (de) 2007-06-13
CA2406206A1 (en) 2001-10-25
ES2288167T3 (es) 2008-01-01
WO2001078696A2 (en) 2001-10-25
CA2406206C (en) 2012-03-20
WO2001078696A3 (en) 2002-03-14

Similar Documents

Publication Publication Date Title
DE60128902D1 (de) Formulierungen zur verwendung in inhalationsvorrichtungen
MXPA02010213A (es) Mejoras en, o relacionadas con formulaciones para usarse en aparatos inhiladores.
ATE271383T1 (de) Pulverformulierung zur inhalation
MY119074A (en) Pharmaceutical aerosol composition
CY1107350T1 (el) Εισπνευστηρας ξηρης σκονης πολλαπλων δοσεων με δεξαμενη σκονης
ATE274955T1 (de) Arzneizusammensetzungen zur aerosolbildung und zu inhalationszwecken
NO973502D0 (no) Bærerpartikler for anvendelse i törre pulverinhalatorer
TR200101442T2 (tr) HFA 227 ve HFA 137 ihtiva eden farmasötik aeorosol bileşimi
YU49279B (sh) Postupak za pripremanje farmaceutske formulacije za dobijanje leka za inhalacionu primenu
AU1850302A (en) Powdery preparations and proecss for producing the same
DK0871430T4 (da) Pulvere og anvendelse til i törpulverinhalatorer
AU2001284072A1 (en) A device for determining the size distribution of aerosol particles
DE69907717D1 (de) Pharmazeutische formulierung in form eines trockenen pulvers
YU48708B (sh) Nosač obložen sa praškastim farmaceutskim preparatom, postupak za pripremu nosača i postupak za doziranje praškova za inhaliranje
ATE424186T1 (de) Medizinische aerosolzusammensetzungen mit einem funktionalisierten polyethylenglykol-hilfsstoff
NZ513981A (en) Delivery of microparticle formulations using needleless syringe device for sustained-release of bioactive compounds
UY26653A1 (es) Producto sólido blando estable y eficaz

Legal Events

Date Code Title Description
8363 Opposition against the patent